Fanapt® is an atypical antipsychotic approved for the treatment of schizophrenia in adults. Fanapt® is a serotonin (5-HT2) receptor and dopamine receptor antagonist.
Under an agreement with Vanda, Novartis has development and commercial rights to Fanapt® in the US and Canada. Fanapt® was granted US Market Approval by the FDA in May 2009. In addition, Vanda currently has Fanapt® distribution partnerships in Israel and Mexico. In 2012, Fanapt® was approved for marketing in Israel and Argentina.
For U.S. full prescribing information, including box warnings and safety information, please visit www.fanapt.com.